Agenus AACR 2026 data show immune reprogramming signal in PD-1 refractory gastroesophageal cancer
Read how Agenus’ AACR 2026 data could reshape treatment sequencing in refractory gastroesophageal cancer and what risks still matter.
AACR 2026: Can Zai Lab’s zocilurtatug pelitecan change the treatment picture for small cell lung cancer brain metastases?
Read how Zai Lab’s zocilurtatug pelitecan posted strong AACR 2026 data in SCLC brain metastases and NECs, and what it could change next.
How JANX014 expands Janux Therapeutics’ tumor-activated platform strategy in prostate cancer immunotherapy
Janux Therapeutics advances JANX014 into Phase 1 for prostate cancer. Discover what this means for PSMA therapies and T cell engager safety.
What Medicus Pharma Ltd.’s SkinJect application signals for Hedgehog pathway-driven cancers
Discover how SkinJect’s orphan drug bid could reshape Hedgehog-driven cancer treatment. Read what it means for clinicians, regulators, and investors.
Why Bioxodes’ adaptive trial strategy could accelerate approval timelines in stroke therapeutics
Bioxodes advances BIOX-101 into pivotal trials for intracerebral hemorrhage. Find out how this strategy could reshape stroke treatment pathways.
What Kura Oncology’s latest data reveals about resistance biology in kidney cancer
Can darlifarnib overcome VEGF resistance in kidney cancer? Explore what Kura Oncology’s latest data could mean for future treatment strategies.
Can Fate Therapeutics, Inc. solve the conditioning chemotherapy problem in CAR T?
Discover how FT839’s conditioning-free CAR T platform could reshape cancer and autoimmune treatment pathways. Read the full analysis now.
Could Ampligen become a late-stage pancreatic cancer breakthrough after AIM ImmunoTech’s latest clinical push?
Can Ampligen’s Phase 3 push reshape pancreatic cancer treatment? Read how AIM ImmunoTech’s latest clinical progress could change the oncology outlook.
What the new J-code means for Glaukos’ Epioxa launch and the future of keratoconus reimbursement
Glaukos secures a permanent J-code for Epioxa. Read why this reimbursement milestone could shape keratoconus treatment adoption and payer access.
Molgramostim review pushed to November: what Savara’s FDA delay means for autoimmune PAP
Savara’s molgramostim FDA review was extended to November 22, 2026. Read what this means for autoimmune PAP, launch timing, and regulatory risk.